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Abstract
Purpose: Dopamine receptors are involved in pathophysiology of neuropsychiatric
diseases, including Huntington’s disease (HD). PET imaging of dopamine D2 receptors
(D2R) in HD patients has demonstrated 40% decrease in D2R binding in striatum, and
D2R could be a reliable quantitative target to monitor disease progression. A D2/3R
antagonist, [18F] fallypride, is a high-affinity radioligand that has been clinically used to
study receptor density and occupancy in neuropsychiatric disorders. Here we report an
improved synthesis method for [18F]fallypride. In addition, high molar activity of the
ligand has allowed us to apply PET imaging to characterize D2/D3 receptor density in
striatum of the recently developed zQ175DN knock-in (KI) mouse model of HD.
Methods: We longitudinally characterized in vivo [18F] fallypride -PET imaging of D2/D3
receptor densities in striatum of 9 and 12month old wild type (WT) and heterozygous
(HET) zQ175DN KI mouse. Furthermore, we verified the D2/D3 receptor density in
striatum with [3H] fallypride autoradiography at 12months of age.
Results: We implemented an improved synthesis method for [18F] fallypride to yield high
molar activity (MA, 298–360 GBq/μmol) and good reproducibility. In the HET zQ175DN KI
mice, we observed a significant longitudinal decrease in binding potential (BPND) (30.2%,
p < 0.001, 9months of age and 51.6%, p < 0.001, 12months of age) compared to WT
littermates. No mass effect was observed when the MA of [18F] fallypride was > 100 GBq/
μmol at the time of injection. Furthermore, the decrease of D2/D3 receptor density in
striatum in HET zQ175DN KI was consistent using [3H] fallypride autoradiography.
Conclusions: We observed a significant decrease in D2/D3R receptor densities in the
striatum of HET zQ175DN KI mice compared to WT mice at 9 and 12months of age.
These results are in line with clinical findings in HD patients, suggesting [18F] fallypride
PET imaging has potential as a quantitative translational approach to monitor disease
progression in preclinical studies.
Keywords: Huntington’s disease, [18F] fallypride, PET, Autoradiography, Translational
imaging
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Introduction
Huntington’s disease (HD) is a devastating hereditary autosomal progressive neurode-
generative disorder. Clinical features of HD include chorea, cognitive dysfunction, and
psychiatric symptoms that are caused by excessive repeat of CAG trinucleotide in the
huntingtin gene (Htt) (MacDonald et al. 1993). Currently, symptomatic treatment is
the only available option for HD (Vattakatuchery and Kurien 2013).
Alterations in the dopaminergic system play an important role in the pathophysiology of
HD and other neuropsychiatric diseases such as Parkinson’s and Alzheimer’s disease,
schizophrenia, and multiple sclerosis (Rangel-Barajas et al. 2015). Dopamine (DA) receptors
are subdivided into D1-like and D2-like receptor families, and reduced density and activity
of these receptors has been reported in the striatum of early-manifest HD patients
(Niccolini et al. 2014). In another study about 40% reduction in binding of [11C]SCH23390
and [11C] raclopride to D1R and D2R, respectively, has been reported in HD patients
(Ginovart et al. 1997). Reduction in radioligand binding was also significantly associated
with the duration of symptoms, suggesting these receptors could be reliable quantitative tar-
gets to monitor disease progression (Niccolini et al. 2014; Ginovart et al. 1997).
[11C] Raclopride is a widely used tracer in D2R PET imaging (Niccolini et al. 2014;
Ginovart et al. 1997) but, due to the short half-life of [11C] (20.3 min), [18F] based radi-
oligands with a longer half-life (109.8 min) have been developed for use without close
vicinity to a medical cyclotron. [18F] fallypride is a potent D2/D3 receptor antagonist,
which has substantially higher affinity (33 pmol/L) to D2/D3 receptors compared to
[11C] raclopride (26 nmol/L) in healthy humans, suggesting it could potentially be a
useful agent to monitor neurodegenerative disease progression in HD (Mukherjee et al.
1995; Siessmeier et al. 2005; Elsinga et al. 2006).
Current HD mouse models include transgenic (TG) and knock-in (KI) models, of
which KI model develops disease pathophysiology more slowly (Ehrnhoefer et al. 2009).
The studied zQ175 delta neo KI (zQ175DN KI) mouse model is based on the estab-
lished zQ175 KI mouse line that has been extensively characterized in molecular, be-
havioral, and imaging studies (Heikkinen et al. 2012; Menalled et al. 2012; Smith et al.
2014; Häggkvist et al. 2017). The zQ175 KI mouse model has an expanded CAG repeat
in exon 1 of mouse Htt gene and already exhibits a HD-like phenotype when heterozy-
gous (HET). However, the zQ175 KI allele has a neomycin resistance cassette in the
Htt gene locus, which has been removed in the zQ175DN KI strain. This new strain
has not been as well characterized as its predecessor, but recently it was reported that
onset of HD-like symptoms appear earlier and disease pathology develops more rapidly
in zQ175DN KI mice than in zQ175 KI mice (Heikkinen et al. 2017).
Applying [18F] fallypride to mouse PET imaging could significantly improve through-
put compared to [11C] raclopride, with some potential caveats. For example, in rodent
D2R/D3R imaging, low molar activity may affect the results as too high of an injected
mass may cause saturation of the receptors (Alexoff et al. 2003). Therefore, a highly op-
timized synthesis method is crucial for successful PET imaging in rodents. Here we
present an improved synthesis method for [18F]fallypride. We also characterized the
zQ175DN KI mouse in vivo using [18F] fallypride PET imaging and ex vivo [3H] fally-
pride autoradiography, following the progression of phenotype with PET scans at the
age of 9–10 months and again at 12–13months. Finally, we applied autoradiography to
the measure of D2/D3 receptor density in the striatum.
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Materials and methods
Chemicals and instrumentation
All chemicals and solvents were purchased from Sigma-Aldrich (Milwaukee, WI, USA)
and used without further purification. Carbonated QMA light and C18 light cartridges
were purchased from Waters (Milford, MA, USA), sterile Millex-GV filters (0.22 μm)
were purchased from Millipore (Billerica, MA, USA), absolute ethanol was purchased
from Altia (Finland) and sterile water and saline were purchased from Braun. Sterile
15 mL vials were purchased from Comecer (Italia).
Semi-preparative high-performance liquid chromatography (HPLC) was conducted in
the GE TRACERlab™ FX2-N under the following HPLC conditions: Phenomenex Luna
(C2) C18 column, 250 × 10 mm, 5 μm; ACN:Water 40/60 + 0.1 M ammoniumformate;
4 mL/min. Analytical HPLC was performed using an Agilent 1260 HPLC system, which
includes a quaternary gradient pump, a variable wavelength detector, and a radioactiv-
ity-HPLC-flow detector. Analytical HPLC was performed under the following condi-
tions: Phenomenex Kinetex C18 4.6 × 50mm, 5 μm, ACN:Water 37:63 + 0.1% TFA, 2
mL/min.
The elution efficiency of [18F] fluoride ion from a carbonated QMA light cartridge
was evaluated with K2CO3 and Kryptofix 2.2.2. Acetonitrile (ACN)/water/theoxylalco-
hol was used as the eluent for eluting trapped [18F] fluoride ion. The results (data not
shown) indicated that 0.8 mg K2CO3 and 9.1 mg K222 were able to eluate the [18F]
fluoride ion from Waters QMA light cartridge. Reducing the amount of K2CO3 to 0.5
mg decreased the eluation efficacy.
Synthesis of [18F]fallypride
When imaging rodents, especially mice with limited neuroreceptors, high molar activity
radioligands should be used to enable reliable quantification of differenes between indi-
viduals. For this purpose, improved synthesis method was established. Overview of the
reaction is shown in Scheme 1. The optimized radiosynthesis of [18F] fallypride was
completed via the following procedure: 1) [18F] fluorination, 2) HPLC purification, and
3) formulation. The synthesis of [18F] fallypride consisted of seven (7) reagent vials on
the FX2-N module. Vial 1 was used for the elution. Vial 3 was used for precursor; vials
4–5 for quenching reagent; vials 12–13 for the formulation of purified [18F]fallypride;
and vial 14 for the washing of C18 cartridge after trapping the final product from
HPLC. Vial 1 was added with fresh 9.1 mg K222, 0.8 mg K2CO3 in 1.1 mL ACN,
thexyl-alcohol, water (8:2:1); Vial 3 was added with the tosylate precursor (0.8 mg) in
ACN (0.8 mL); Vial 4 was added with 30:70 ACN:water solvent (2 mL); Vial 5 was
Scheme 1 The reaction scheme for the synthesis of [18F]fallypride.
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added with HPLC solvent (1 mL); Vial 12 was added with saline (7 mL); Vial 13 was
added with EtOH (0.7 mL); Vial 14 was added with sterile water (10 mL); and an HPLC
dilution flask was added with water (30 mL).
Typically, 37 GBq (1 Ci) [18F] fluoride in 2.5 mL of water was passed through the
QMA cartridge and dried with helium flow. [18F] Fluoride was eluted from the cart-
ridge into reactor 1 (R1) with the eluent in Vial 1, and azeotropically dried at 55 °C with
N2 flow for 3 min and at 75 °C for 3 min under N2/vacuum. The activity was further
dried using a vacuum for 5 min. The [18F] fluoride drying cycle took about 11 min. The
tosylate precursor in Vial 3 was added to the dried activity. The resulting solution was
stirred at 100 °C for 10 min, and cooled to 45 °C. The reaction mixture was diluted with
30:70 ACN:water (Vial 4), and transferred to an intermediate tube. Reactor 1 was rinsed
with another portion of ACN:water (Vial 5) and the solution was also transferred to an
intermediate tube. The solution in Tube 2 was thoroughly mixed by bubbling N2 for
15 s and injected into the HPLC for purification. The labeled product was eluted at
about 16 min. The product peak was collected in the dilution flask containing 30 mL of
water, and passed through a Waters C18 light cartridge (pre-conditioned with 5 mL of
water, 5 mL of ethanol, and 5 mL of water). The trapped intermediate was rinsed with
10mL of water (Vial 14), and eluted with 0.7 mL of absolute ethanol (Vial 13) after
which the C18 cartridge was rinsed with 7 mL of sterile saline. The content was trans-
ferred into the final product vial with an in-line sterile filter.
The chemical identity, MA, and radiochemical purity (RCP) of the [18F] fallypride
was checked by analytical HPLC or radio-TLC. The stability of the product was verified
until next day (18 h, HPLC).
Animals
All animal experiments were carried out according to the National Institutes of Health
(NIH, U.S.) guidelines for the care and use of laboratory animals and approved by the
National Animal Experiment Board (Finland). The animal facility has been accredited
by the Association for Assessment and Accreditation of Laboratory Animal Care Inter-
national (AAALAC). All procedures performed in studies involving animals were in ac-
cordance with the ethical standards of the institution or practice at which the studies
were conducted.
Eight-month-old male HET zQ175DN KI mice and their WT littermates were pur-
chased from Jackson Laboratories. In order to prevent fighting between male mice
housed together, the studied male mice were housed separately in individually venti-
lated cages accompanied with a female for the entire study duration. The mice had ac-
cess to chow and water ad libitum. Prior to accepting the mice to the study, they were
screened for abnormal liver function with Diazyme Total Bile Acids Assay (Diazyme
Europe GmbH, Dresden, Germany) from plasma samples.
PET imaging and image analysis
The mice were anesthetized using isoflurane (4–5% induction, 1.5–2% maintenance)
and cannulated in the lateral tail vein. The cannula was filled with heparinized saline
(100 IU/mL) to prevent blood coagulating in the cannula. Three mice were cannulated
simultaneously and transferred into a scanner (BioPET/CT, Sedecal, Spain) equipped
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with a heated small animal bed with a holder for three mice (Minerve Veterinary
Equipment, France). The rectal temperature and breathing rate of the animals were
monitored during the scan and adjusted accordingly to 37 °C and 70–90 bpm. A bolus
of [18F] fallypride (150 μL; mean 9.7MBq; MA > 100 GBq/μmol) was administrated 30 s
after the start of the dynamic PET scan. List mode data was acquired for 90.5 min. After
each PET scan a CT scan was performed (140 μA, 45 kV) for information on individual
animal orientation and attenuation map for image reconstruction. The acquired sino-
grams were reconstructed with 3D OSEM (1 iteration, 25 subsets) applying attenuation
correction into 30 time frames (1 × 30 s; 4 × 10 s; 4 × 20 s; 4 × 60 s; 6 × 180 s; 11 × 360 s).
The dynamic PET images were analyzed with PMOD software v3.7 (PMOD Tech-
nologies Ltd., Zürich, Switzerland). The PET images were co-registered with an
in-house reconstructed MRI template created from the image MRI of average 12-
month-old WT and HET zQ175 KI mice (n = 10/genotype). Volumes of interest (VOIs)
of striatum and cerebellum of the template were used. The VOI of cerebellum had a re-
duced size to prevent spillover signal from defluorinated [18F] fluoride uoride accumu-
lating into bones of the skull. The dynamic PET data was fitted to a simplified
reference tissue model (Lammertsma and Hume 1996) and the nondisplaceable binding
potential (BPND) of [
18F] fallypride was measured in the striatum. Average standardized
uptake value (SUV) images from each group and time activity curves (TAC) from stri-
atum and cerebellum were calculated.
Autoradiography
After the PET imaging at the age of 12 months the mice were decapitated and their
brains were quickly frozen in dry ice-cooled isopentane (− 55° – -45 °C) and stored at
− 80 °C until sectioning. The brains were cryosectioned into 20 μm thick slices and
mounted on superfrost glass slides (Thermo scientific) and stored at − 80 °C until stain-
ing. The slides were quickly thawed under a stream of air and incubated with [3H] fally-
pride (80.6 Ci/mmol, 1470, RC Tritec AG) in assay buffer (50 mM Tris-HCl, 1 mM
EDTA, 100mM NaCl, 5 mM MgCl2, pH 7.4) for 60 min at room temperature. To deter-
mine Bmax for D2/D3R the slides were incubated with the following ligand concentra-
tions: 0.01, 0.05, 0.1, 0.2, 0.5, 1.0, 1.5, 2.0, 5.0, and 10.0 nM. Non-specific binding was
measured by competing the radioligand against 10 μM of unlabeled fallypride. After the
incubation, the slides were washed 2 × 5min in 50 mM Tris-HCl, 5 mM MgCl2 pH 7.4,
and milliQ water. Digital autoradiography images were acquired with BetaImager
TRacer (BiospaceLab, France) with 6 h exposure time. ROIs were manually drawn on
striatum using M3 Vision software (v1.0.6.1035, BiospaceLab, France) and specific
binding was calculated as the difference of total and non-spesific binding. Non-linear
regression analysis (GraphPad Prism v7.00, GraphPad Software Inc., La Jolla, CA, USA)
was used determine Bmax of D2/D3 receptors.
Statistical analysis
Mean values ± SD are presented for all results. Comparison between groups has been
done with unpaired student’s t-test unless otherwise stated. All statistics and graphs
have been calculated with GraphPad Prism.
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Results
The radiosynthesis of [18F] fallypride was performed with good yield, and its molar ac-
tivity was reproducible. The synthesis route is presened in Sheme 1. In addition, radio-
chemical purity was high (> 99%). The overall synthesis yield was approximately 55%
(non decay corrected) with total synthesis time of 58 min. The stability of the product
up to 18 h was verified using radio-HPLC. Our synthesis method didn’t produce any
carbonated impurities that have previously been observed during [18F] fallypride syn-
thesis. This could be observed from the radio-HPLC chromatograms. The molar activ-
ity (MA) of [18F] fallypride was 300–550 GBq/μmol, which allows two subsequent PET
scans, as opposed to one scan from the typical synthesis batch with MA < 100 GBq/
μmol at the time of injection.
Average PET images showed a high accumulation of [18F] fallypride to the striatum,
whereas no sign of tracer was seen in cerebellum during 45–90min post injection (Fig. 1).
The binding of [18F] fallypride in striatum of HET zQ175DN KI mice was significantly re-
duced compared to their WT littermates. [18F] fallypride had slow kinetics in the striatum,
which could be seen from the TACs (Fig. 2). When individual binding potentials (BP) in-
cluding mean value and SD were calculated using SRTM, the striatum of zQ175DN HET
mice showed a 30.2% decrease in BPND (p < 0.0001) 9 mo and 51.6% decrease (p < 0.0001)
at 12 mo when compared to those in WTs (Fig. 3). BPND of WT showed a 10.1% increase
from 9 to 12 mo, which was not statistically significant. On the other hand, 23.6% de-
crease (p < 0.05) was seen from 9 mo to 12 mo of zQ175KI mice.
As 3 mice were scanned simultaneously, good throughput of 6 mice/synthesis was
achieved. No mass effect and receptor saturation was observed with MA > 100 GBq/
μmol at the time of injection (Fig. 4) as no correlation for injected mass and BPND was
observed (Pearson correlation, Table 1).
In ex vivo autoradiography, 35% reduction in Bmax of [
3H] fallypride in striatum
of HET zQ175DN KI mice was observed in comparison to WT (Extra sum-of-
squares F-test, P < 0.0001). The Bmax values were 327.3 ± 5.4 fmol/g and 206.8 ± 4.6
fmol/g for WT and HET, respectively. The majority of the [3H] fallypride binding
occurred in striatum and nucleus accumbens. Non-specific binding of radioligand
was minimal (Fig. 5).
Fig. 1 Averaged PET images from 45 to 90 min post injection showed higher uptake in the striatum of WT
mice compared to HET both at 9 and 12 months. The PET images have been co-registered with in-house
generated MRI template for visualization
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Discussion
Low abundance of target receptors, accurate tracer kinetics modeling, pharmacological ef-
fects, and toxicity of the imaging probes are examples of why high molecular activity (MA) is
desired in PET imaging. Low MA increases the injected mass of the tracer, which can have
unknown pharmacological effects or even saturate the receptor, biasing the binding potential.
Low MA can affect the results of rodent D2R/D3R imaging when the injected mass is
too high, which causes saturation of the receptors (Alexoff et al. 2003). In the current
study, we observed no mass effect with the animals dosed with an average of 9.7 MBq
with MA > 100 GBq/μmol of [18F]fallypride. This is in line with previous studies where
no mass effect was observed with female BALB/c mice injected with 6MBq of [18F]
fallypride (MA > 50 GBq/μmol) (Rominger et al. 2010).
Previously, optimization of [18F] fallypride synthesis had been done with microfluidic
reactors up to a MA of 730MBq/μmol (Javed et al. 2014); however, batch size using
Fig. 2 Time activity curves of [18F] fallypride in striatum and cerebellum (reference region) at the age of 9
months (a) and 12months (b). Data is presented as % of injected dose/cubic centimeter of
tissue (%ID/cc) ± SD
Fig. 3 Individual and mean ± SD binding potential of [18F] fallypride in WT and HET zQ175DN KI mice.
Statistical analysis using paired two-tailed T-test (gray line) and unpaired two-tailed T-test (black line, ns =
nonsignificant, *** p = 0.005, **** p < 0.0001)
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this process is too small for clinical use and scale-up is difficult. Enhanced reaction kin-
etics can potentially increase the fluorination kinetics of a [18F] fluoride ion in a reactor
during the labeling. Usually the major contaminant of [19F] is found from the target
water, target material, tubings, solvents, and anion exchange resins and reactor wall.
The amount of [19F] is much higher compared to [18F], indicating the MA should be
directly proportional to the amount of [18F] at the start of labeling. However, this is not
always the case and attempts to increase the MA of [18F] fallypride have often failed.
A moderate radiochemical yield (RCY 20–40%) for [18F] fallypride has been reported
(Javed et al. 2014). Long labeling time (15–30min) and high temperatures (over 150 degree
Celsius) are problematic since they usually demand lengthy HPLC purification steps to
avoid mass peaks, especially when using over 2mg of a precursor. The use of high base con-
centrations in the [18F] labeling step is likely to be the main reason for various side products
and consequently low radiochemical yield, particularly in the case of base-sensitive tosyl-
fallypride. Here we synthetized [18F] fallypride by labeling tosyl-fallypride (tosylate precur-
sor) with [18F] fluoride ion using a phase-transfer catalyst in GE’s Tracerlab FX2-N synthesis
module. Using low concentrations of K2CO3 is desirable since high concentrations may lead
to side products. In order to keep the amount of K2CO3 reasonable, we used K2.2.2/K2CO3
(9.1mg/0.8mg). One hypothesis for improved reaction kinetics and increased nucleophilic-
ity of the [18F] fluoride ion is addition of thexyl alcohol into the eluting solution. The elution
was carried out in acetonitrile/theoxylalcohol/water solution (8:2:1, 1.1mL) and the drying
of the [18F] fluoride was carried out in a single step without adding any extra acetonitrile. In
summary, by using a low amount of K2CO3 and with addition of thexyl alcohol, the RCY
Fig. 4 No mass effect to BPND of [
18F] fallypride was observed when using high specific activity (MA > 100
GBq/μmol) at the time of injection. Line represents linear regression of the population
Table 1 Pearson correlation of injected mass of [18F] fallypride and BPND. No significant correlation
was observed
Genotype Pearson r R2 P (two-tailed) n
WT 9 mo 0.334 0.111 0.289 12
HET 9 mo 0.064 0.004 0.844 12
WT 12 mo 0.462 0.213 0.153 11
HET 19 mo −0.393 0.155 0.206 12
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yield was 55% (non decay corrected) with a MA of 300–550GBq/umol. The reaction can
be carried out in 16mL reactor in ACN 10min using a regular heater at 100 °C.
In previous small-animal PET imaging with [11C] raclopride using the zQ175 KI
mouse strain, the BPND difference to WT animals was 40% and 44% at the ages of 6
months and 9months, respectively (Häggkvist et al. 2017). Our results are in line with
these findings, although the results are not fully comparable as the mouse lines are
slightly different, and chemical structures of the tracers are not identical. This is en-
couraging as both [11C] raclopride and [18F] fallypride are well known clinical PET li-
gands for D2/D3 antagonism. For the first time, improved [18F] fallypride ligand
synthesis enabled a proper characterization of the D2/D3 binding potential changes in
HD model using [18F] radiotracer. With improved MA, [18F] fallypride is unique in that
it is the only currently available PET radiotracer that can simultaneously provide quan-
titative measures of D2/D3 receptor binding in the striatum and possibly extrastriatal
brain regions in the same scanning session in HD models, which remains to be tested.
Conclusions
Succesful preclinical PET imaging of neurologically important receptors requires delicate
radiosynthesis outcome to enable quantification of differences between individulas in reli-
able manner. To achieve that, applying improved [18F] fallypride synthesis method in lon-
gitudinal PET imaging, we were able to characterize a longtidinal D2/D3 receptor level
change in striatum of HET zQ175DN KI mice compared to WT mice. This significant de-
cline of D2/D3 receptor binding potentials over time in HD mouse striatum was also con-
firmed by ex vivo autoradiography. As these pathophysiological changes are in line with
clinical findings in HD patients, [18F] fallypride PET imaging can be considered as a quan-
titative therapeutic approach in longitudinal preclinical studies.
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